These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16824361)

  • 21. Issues on the selection of non-inferiority margin in clinical trials.
    Hou Y; Wu XY; Li K
    Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tests for equivalence or non-inferiority--why?
    Drug Ther Bull; 2008 Jul; 46(7):55-6. PubMed ID: 18603641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing the efficiency of clinical trials of antimicrobials: the scientific basis of substantial evidence of effectiveness of drugs.
    Powers JH
    Clin Infect Dis; 2007 Sep; 45 Suppl 2():S153-62. PubMed ID: 17683020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlling the type 1 error rate in non-inferiority trials.
    Snapinn S; Jiang Q
    Stat Med; 2008 Feb; 27(3):371-81. PubMed ID: 17914715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Globalization of cardiovascular clinical research: the balance between meeting medical needs and maintaining scientific standards.
    Stough WG; Zannad F; Pitt B; Goldstein S
    Am Heart J; 2007 Aug; 154(2):232-8. PubMed ID: 17643571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-inferiority trials in surgical oncology.
    Fueglistaler P; Adamina M; Guller U
    Ann Surg Oncol; 2007 May; 14(5):1532-9. PubMed ID: 17294075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness outcomes in attention-deficit/hyperactivity disorder.
    Weiss MD; Gadow K; Wasdell MB
    J Clin Psychiatry; 2006; 67 Suppl 8():38-45. PubMed ID: 16961429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-formulating non-inferiority trials as superiority trials: The case of binary outcomes.
    Durkalski VL; Berger VW
    Biom J; 2009 Feb; 51(1):185-92. PubMed ID: 19197960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. On improving research methodology in clinical trials.
    Berger VW; Matthews JR; Grosch EN
    Stat Methods Med Res; 2008 Jun; 17(3):231-42. PubMed ID: 17925317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statistical and regulatory issues in nonrandomized medical device clinical studies.
    Li H; Yue LQ
    J Biopharm Stat; 2008; 18(1):20-30. PubMed ID: 18161539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current issues in non-inferiority trials.
    Fleming TR
    Stat Med; 2008 Feb; 27(3):317-32. PubMed ID: 17340597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An introductory note to the CHMP guidelines: choice of the non-inferiority margin and data monitoring committees by David Brown, Peter Volkers and Simon Day, Statistics in Medicine 2006; 25:1623-1627.
    Stat Med; 2007 Jan; 26(1):230-3; author reply 234-5. PubMed ID: 16900566
    [No Abstract]   [Full Text] [Related]  

  • 38. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin.
    ; ;
    Stat Med; 2006 May; 25(10):1628-38. PubMed ID: 16639773
    [No Abstract]   [Full Text] [Related]  

  • 40. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.